Traneta M 2.5 mg+500 mg (Tablet)

Indications

• Improves glycemic control in adults with type 2 diabetes mellitus
• Adjunct to diet and exercise
• Appropriate for treatment with both Linagliptin and Metformin Hydrochloride

Pharmacology

• Linagliptin inhibits DPP-4 enzyme
• Increases concentrations of active incretin hormones
• Stimulates insulin release from pancreatic beta cells
• Decreases glucagon secretion from pancreatic alpha cells
• Metformin lowers basal and postprandial plasma glucose
• Decreases hepatic glucose production
• Improves insulin sensitivity

Dosage & Administration

• Individualized dosage based on effectiveness and tolerability
• Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals
• Gradual dose escalation to reduce gastrointestinal side effects
• Recommended starting dose for patients not treated with Metformin Hydrochloride
• Switching from individual components to combination containing same doses

Interaction

• Cationic drugs competition for renal tubular transport systems
• Carbonic anhydrase inhibitors inducing non-anion gap, hyperchloremic metabolic acidosis
• Rifampin decreasing Linagliptin exposure
• Drugs affecting glycemic control leading to loss of glycemic control

Contraindications

• Contraindicated in patients with renal impairment
• Acute or chronic metabolic acidosis (diabetic ketoacidosis)
• Hypersensitivity to Linagliptin or Metformin Hydrochloride

Side Effects

• Most common side effects: nasopharyngitis and diarrhea
• Hypoglycemia more common in patients treated with Traneta M and sulfonylureas

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Caution during lactation

Precautions & Warnings

• Discontinue in case of lactic acidosis or suspected pancreatitis
• Temporary discontinuation for radiologic studies and surgical procedures
• Monitoring of Vitamin B12 levels due to potential decrease
• Advisory on alcohol consumption and other medicines
• Precautions in travel and emergency preparedness

Overdose Effects

• Supportive measures in case of overdose
• Hemodialysis or peritoneal dialysis for Metformin Hydrochloride
• No dose-related clinical adverse drug reactions up to 600 mg of Linagliptin
• Hypoglycemia and lactic acidosis reported in Metformin Hydrochloride overdose

Therapeutic Class

Combination Oral hypoglycemic preparations

Storage Conditions

Cool & dry place (below 30°C), protected from light & moisture, Keep out of the reach of children

Related Brands

• Traneta M 2.5 mg+850 mg (Tablet) - beximco-pharmaceuticals-ltd
• Traneta M 2.5 mg+1000 mg (Tablet) - beximco-pharmaceuticals-ltd
• Linatin M 2.5 mg+500 mg (Tablet) - delta-pharma-ltd
• Linarol-M 2.5 mg+500 mg (Tablet) - drug-international-ltd
• Linarol-M 2.5 mg+850 mg (Tablet) - drug-international-ltd